The Approval of 68Ga-PSMA-11: What You Need to Know
Sponsored by the SNMMI Clinical Trials Network
Thomas Hope, MD, University of California, San Francisco
Jeremie Calais, MD, MSc, University of California, Los Angeles
Shaojun Zhu, MSc, MSRS, RAC, University of California, Los Angeles
December 2020 started off with exciting news of UCLA and UCSF’s approval of 68Ga-PSMA-11 for prostate cancer patients with suspected metastases or suspected recurrence based on elevated serum prostate-specific antigen (PSA). This course will help nuclear medicine and referring physicians, technologists, radiochemists, and regulatory specialists navigate through patient selection, PSMA PET imaging interpretation, the approval process and regulatory considerations for the availability of 68Ga-PSMA-11.
1. Identify the role of PSMA PET Imaging in prostate cancer management.
2. Describe patient selection and utilization of PSMA PET in the clinic.
3. Explain the regulatory landscape of the PSMA PET approval and availability in the US.
CE Credit applications for physicians, pharmacists, physicists and technologists are pending. Check back for updates regarding CE Credit status.